**Document No. 06**

**Invitation to offer for NHS National Pharmaceuticals Transition 2020\_2**

**Offer reference number: CM/PHG/20/5618**

**Period of framework agreement: The total maximum duration of the framework agreement to be no more than 38 months (19 months plus options to extend (at the Authority's sole discretion) for up to a further 19 months)**

**Potential periods of call-offs under the framework agreement**

**Transition Products: LSNE 01/12/2020 to 30/09/2021 (10 months)**

**NWLN 01/12/2020 to 31/01/2022 (14 months)**

**CESW 01/12/2020 to 30/06/2022 (19 months)**

**Hospital Only Products: All Regions 01/12/2020 to 31/01/2022 (14 months)**

**Form of offer**

‘the Offeror’

**Agrees:**

1. That this offer and any contracts arising from it shall be subject to the Terms of Offer, the Framework Agreement and Terms and Conditions and all other terms (if any) issued with the Invitation to offer; and

2. if its offer is accepted, to enter into the framework agreement with The NHS Commissioning Board (Operating Under the Name of NHS England) (‘Authority’) and thereafter to supply the goods and/or services in respect of which its offer is accepted to the exact quality, sort and price specified in the Offer schedule in such quantities, to such extent and at such times and locations as ordered;

3. that this offer is made in good faith and that the Offeror has not fixed or adjusted the amount of the offer by or in accordance with any agreement or arrangement with any other person. The Offeror certifies that it has not and undertakes that it will not:

3.1 communicate to any person other than the person inviting these offers the amount or approximate amount of the offer, except where the disclosure, in confidence, of the approximate amount of the offer was necessary to obtain quotations required for the preparation of the offer, for insurance purposes or for a contract guarantee bond;

3.2 enter into any arrangement or agreement with any other person that he or the other person(s) shall refrain from making an offer or as to the amount of any offer to be submitted; and

1. that the Authority may disclose the Offeror’s information/documentation (provided to the Authority during this procurement exercise) more widely within Government for the purpose of ensuring effective cross-Government procurement processes, including value for money and related purposes.

**Completion and acceptance of this form is undertaken on the Bravo Solution e-Tendering portal under “My Response”**